Licochalcone A / NRF2 Cancer Research Results

LCA, Licochalcone A: Click to Expand ⟱
Features:

Licochalcone A - Licorice-Derived Chalcone

Type: Natural chalcone / flavonoid-related phytochemical

Sources: Found primarily in licorice species including Glycyrrhiza inflata and related Glycyrrhiza plants.

Function: Licochalcone A is a bioactive chalcone with anticancer, anti-inflammatory, antioxidant, antimicrobial, and metabolic effects. Reported mechanisms include modulation of PI3K/AKT, MAPK, NF-κB, STAT3, ROS, apoptosis, autophagy, and cell-cycle regulatory pathways.

Cancer: Preclinical studies demonstrate inhibition of cancer-cell proliferation, migration, invasion, and metastasis, together with induction of apoptosis, autophagy, oxidative stress, and cell-cycle arrest. LCA has shown anticancer activity in breast, lung, gastric, colorectal, prostate, liver, ovarian, and other experimental cancer models.

Alzheimer's Disease: Preclinical evidence suggests neuroprotective and anti-inflammatory effects relevant to neurodegeneration, including suppression of oxidative stress and inflammatory signaling, although the Alzheimer's-specific evidence is less developed than the cancer literature.

Licochalcone A — a naturally occurring prenylated chalcone and phenolic phytochemical found principally in licorice species, especially Glycyrrhiza inflata. It is classified as a natural chalcone/flavonoid-related small molecule and is commonly abbreviated LCA, LicA, or Lico A. Its experimental pharmacology is strongly context-dependent: in many cancer models LCA promotes oxidative stress, mitochondrial dysfunction, apoptosis, autophagy, cell-cycle arrest, and suppression of proliferative and inflammatory signaling, whereas in non-malignant injury models it can activate NRF2-dependent antioxidant defenses. Anticancer development remains preclinical.

Primary mechanisms (ranked):

  1. ROS/redox disruption through mitochondrial ROS generation and inhibition of antioxidant systems including TrxR1, promoting oxidative-stress-mediated cancer-cell death.
  2. PI3K/AKT/mTOR suppression, reducing survival signaling and frequently promoting apoptosis and autophagy.
  3. Mitochondrial and endoplasmic-reticulum stress-mediated apoptosis involving mitochondrial membrane depolarization, cytochrome c release, caspase activation, PARP cleavage, and CHOP signaling.
  4. STAT3 suppression, including reduced STAT3 protein/activation and downstream survival and proliferative signaling.
  5. NF-κB and Ras/Raf/MEK pathway suppression, including reduced PD-L1 expression and tumor-cell immune-evasion signaling in experimental models.
  6. Cell-cycle arrest through modulation of cyclins, CDKs, p21/p27, survivin, and related regulatory proteins.
  7. HIF-1α suppression through inhibition of mitochondrial respiration and restoration of intracellular oxygen availability under hypoxic conditions.
  8. Ferroptosis induction in selected models through increased lipid oxidative stress and suppression of the IGF2BP3/MDM2 axis.
  9. Suppression of migration, invasion, angiogenic signaling, and EMT-associated pathways including MAPK/AKT, VEGF, ICAM-1, and related regulators.
  10. NRF2 modulation (context-dependent): NRF2 can be suppressed in some cancer cells, increasing ROS susceptibility, while NRF2 is activated in non-malignant cells and tissues, producing antioxidant and cytoprotective effects.

Bioavailability / PK relevance: Free oral LCA has poor systemic exposure; a rat pharmacokinetic study reported absolute oral bioavailability of approximately 3.3%. Poor aqueous solubility, limited permeability, intestinal first-pass metabolism, glucuronidation, and other metabolic pathways constrain exposure. Formulation materially changes PK: a self-microemulsifying drug-delivery system increased oral bioavailability approximately 2.36-fold in rats, while nanoparticle approaches have produced still larger increases experimentally. LCA also inhibits P-glycoprotein and several CYP enzymes, particularly CYP3A and CYP2C9 in experimental systems, creating a potential drug-interaction concern.

In-vitro vs systemic exposure relevance: Many anticancer experiments use approximately 10–100 μM LCA, with several reported IC50 values in the tens of micromolar range. These concentrations are difficult to reconcile with the low systemic exposure of unformulated oral LCA, so direct translation of conventional cell-culture concentrations to achievable human systemic exposure is uncertain. Delivery systems, local exposure, metabolites, and combination strategies may alter this limitation.

Clinical evidence status: Cancer: preclinical only, with cell-culture and animal xenograft evidence but no established anticancer efficacy in humans. Human exposure evidence is substantially stronger for topical dermatologic/cosmetic use: randomized or prospective studies have evaluated LCA-containing formulations for acne, dermatitis, erythema, and rosacea. LCA is not an established systemic oncology drug. Current translational priorities are exposure optimization, human PK, dose-limiting safety characterization, and controlled oncology trials.

Licochalcone A Cancer Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS and TrxR1 redox disruption ROS ↑; TrxR1 ↓; GSH ↓ ROS ↓ in oxidative-injury models (context-dependent) P/R Oxidative-stress-mediated cancer-cell death ROS generation is mechanistically central in gastric, colorectal, bladder, ovarian, and other models. ROS scavenging with NAC can substantially attenuate LCA-induced apoptosis.
2 PI3K AKT mTOR survival signaling PI3K ↓; AKT ↓; mTOR ↓ AKT ↑ can contribute to NRF2 protection (context-dependent) R/G Survival inhibition, apoptosis, autophagy Strong recurring cancer mechanism, but signaling direction differs in cytoprotective non-cancer models.
3 Mitochondrial apoptosis Mitochondrial membrane potential ↓; cytochrome c ↑; caspase-9/3 ↑; PARP cleavage ↑ Apoptosis ↓ in several oxidative-injury models R/G Intrinsic apoptotic cell death Often downstream of ROS generation; supported across multiple cancer types.
4 Endoplasmic reticulum stress CHOP GRP78 ↑; CHOP ↑; ER stress ↑; caspase signaling ↑ ER-stress injury ↓ in neuroprotective models R/G ER-stress-mediated apoptosis Reported in bladder, lung, and endometrial cancer; cellular context determines whether ER stress is promoted or suppressed.
5 STAT3 signaling STAT3 ↓; p-STAT3 ↓ Not established R/G Reduced survival and proliferation Demonstrated in ovarian and cholangiocarcinoma models; downstream effects include altered mTOR-associated translation and survival proteins.
6 NF-κB and inflammatory survival signaling NF-κB p65 ↓ NF-κB inflammatory activation ↓ R/G Reduced proliferation, inflammation, migration, and immune-evasion signaling Unlike ROS and NRF2, NF-κB suppression is directionally similar in many malignant and non-malignant inflammatory models.
7 PD-L1 and Ras Raf MEK immune-evasion axis PD-L1 ↓; Ras ↓; NF-κB interaction ↓ Cytotoxic T-cell activity ↑ in co-culture G Reduced tumor immune evasion Colon-cancer experiments showed enhanced T-cell-mediated tumor-cell killing after LCA pretreatment; remains preclinical.
8 Cell-cycle regulation G0/G1 or G2/M arrest ↑; cyclin/CDK signaling ↓ Variable G Cytostatic growth inhibition The arrest point is cell-type-dependent. Cyclin D1, cyclin B1, CDK1, survivin, p21, and related regulators have been implicated.
9 Autophagy and LC3 signaling LC3-II ↑; autophagic flux ↑ Context-dependent G Autophagic response accompanying growth inhibition Prominent in breast and NSCLC models. Autophagy is not consistently required for LCA-induced apoptosis.
10 HIF-1α and mitochondrial respiration Mitochondrial respiration ↓; intracellular O2 ↑; HIF-1α ↓; GLUT1 ↓; PDK1 ↓ Not established P/R Suppression of hypoxic tumor adaptation LCA directly suppresses mitochondrial oxygen consumption, promoting oxygen-dependent HIF-1α degradation under hypoxia.
11 Energy metabolism Mitochondrial ATP production ↓; total ATP ↓ Not established P/R Energetic stress Observed with HIF-1α inhibition. The major demonstrated effect is inhibition of mitochondrial respiration rather than direct blockade of glycolysis.
12 Ferroptosis IGF2BP3 MDM2 IGF2BP3 ↓; MDM2 ↓; lipid ROS ↑; MDA ↑; GSH ↓; ferroptosis ↑ Not established R/G Ferroptotic cell death Demonstrated particularly in acute myeloid leukemia; currently less broadly established than apoptotic mechanisms.
13 MAPK JNK p38 ERK signaling JNK/p38/ERK modulation (model-dependent) ERK ↑ can support NRF2 activation (context-dependent) R/G Apoptosis and stress-response regulation In several cancer models JNK/p38 activation contributes to apoptosis, whereas inhibition of MAPK-associated motility signaling has also been reported.
14 Migration invasion and EMT Migration ↓; invasion ↓; vimentin ↓; EMT signaling ↓ Not established G Reduced metastatic phenotype Includes modulation of MAPK/AKT, adhesion proteins, VEGF, and ICAM-1; evidence is preclinical.
15 NRF2 antioxidant response NRF2 ↓ in selected tumors (context-dependent) NRF2 ↑; HO-1 ↑; GCLC/GCLM ↑ R/G Opposing redox effects according to cellular context Particularly important for interpretation: LCA can suppress NRF2 and increase ROS in some cancers while activating NRF2 and protecting normal tissues from oxidative injury.
16 Chemosensitization Drug-induced apoptosis ↑ (model-dependent) Not established R/G Enhanced anticancer drug response LCA enhanced geldanamycin-induced ROS generation, mitochondrial apoptosis, and caspase activation in ovarian cancer cells; no established clinical combination regimen.
17 Clinical Translation Constraint Systemic exposure limited CYP and transporter interactions possible G Limits translation of high-concentration in-vitro effects Free oral bioavailability in rats has been reported at approximately 3.3%. Poor solubility and first-pass metabolism are important constraints. LCA inhibits CYP3A4, CYP2C9, and P-gp experimentally; formulation can substantially increase exposure.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr



Alzheimer's disease relevance: Licochalcone A now has meaningful disease-specific preclinical evidence rather than only general neuroprotective plausibility. Studies in transgenic AD mouse models report improved cognition together with reduced Aβ burden, reduced neuroinflammation, improved insulin/glucose signaling, inhibition of ER-stress-mediated neuronal apoptosis, and NRF2-associated protection. A 2026 APP/PS1 study reported improved memory, increased synaptic markers, reduced Aβ42 and plaque burden, improved glucose handling, and reduced glial activation after 15 mg/kg/day intraperitoneal LCA for four weeks. A separate transgenic mouse study found inhibition of PERK/eIF2α/ATF4/CHOP ER-stress signaling and neuronal apoptosis. Evidence remains preclinical; there is no established human AD efficacy.

Primary AD mechanisms (ranked):

  1. Reduction of Aβ accumulation and plaque burden.
  2. Suppression of ER-stress-mediated neuronal apoptosis through PERK/eIF2α/ATF4/CHOP inhibition.
  3. Reduction of neuroinflammation and glial activation.
  4. Improvement of brain insulin/glucose signaling and GLUT1-associated metabolic function.
  5. NRF2-dependent antioxidant and neuronal stress protection.
  6. Preservation of synaptic structure and plasticity.
  7. Reduction of tau misfolding and tau-associated oxidative stress in cellular models.

Clinical evidence status: Preclinical. Evidence includes cell studies and multiple transgenic mouse AD models, including disease-specific studies published in 2025 and 2026. Human efficacy, optimal systemic dose, CNS pharmacokinetics, and long-term safety have not been established.

Licochalcone A Alzheimer Mechanisms

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Amyloid beta burden Aβ42 ↓; plaque burden ↓ Reduced amyloid pathology Demonstrated in transgenic mouse AD models; earlier cellular and biochemical work also supports interference with Aβ aggregation.
2 PERK eIF2α ATF4 CHOP ER stress ER stress ↓; CHOP signaling ↓ Reduced neuronal apoptosis Mechanistically supported in triple-transgenic AD mice and primary hippocampal neurons.
3 Neuroinflammation and glial activation Glial reactivity ↓; inflammatory signaling ↓; TREM2 ↓ (model-dependent) Reduced chronic neuroinflammatory burden Consistent with broader LCA suppression of TLR4, NF-κB, and MAPK inflammatory signaling.
4 Brain insulin and glucose signaling Insulin response ↑; Insr ↑; GLUT1 ↑ Improved cerebral metabolic function Reported in APP/PS1 mice together with improved systemic glucose tolerance.
5 NRF2 antioxidant signaling NRF2 ↑; antioxidant defense ↑ Reduced oxidative and ER stress NRF2 inhibition reduces LCA neuroprotective effects in experimental systems, supporting a causal contribution.
6 Synaptic plasticity PSD95 ↑; spinophilin ↑; dendritic spine density ↑ Improved neuronal connectivity and memory-associated plasticity Observed in the 2026 APP/PS1 mouse study together with improvement in behavioral memory tests.
7 Tau proteostasis Tau misfolding ↓; tau-associated ROS ↓ Reduced tau-associated cellular toxicity Supported principally by cellular tau-misfolding models; less developed in vivo than the amyloid and ER-stress evidence.
8 Clinical Translation Constraint Human efficacy not established Limits clinical interpretation Animal studies support CNS activity, but human brain exposure, oral dosing requirements, chronic safety, and disease-modifying efficacy remain unknown.


NRF2, nuclear factor erythroid 2-related factor 2: Click to Expand ⟱
Source: TCGA
Type: Antiapoptotic
Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response.
-One way to estimate Nrf2 induction is through the expression of NQO1.
NQO1, the most potent inducer:
SFN 0.2 μM,
quercetin (2.5 μM),
curcumin (2.7 μM),
Silymarin (3.6 μM),
tamoxifen (5.9 μM),
genistein (6.2 μM ),
beta-carotene (7.2μM),
lutein (17 μM),
resveratrol (21 μM),
indol-3-carbinol (50 μM),
chlorophyll (250 μM),
alpha-cryptoxanthin (1.8 mM),
and zeaxanthin (2.2 mM)

1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects.
2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death.
3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress

-In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies.
-Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate.
Decreased Nrf2 expression: Skine, Liver, Pancreatic.
-Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer
- "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1.

Nrf2 Inhibitors and Activators
Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin
Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api
- potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany

Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue.
– In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis.
– In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity.
– This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming.
– Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies.
– High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types.
– While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression.

NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS).
-Brusatol: most cited natural inhibitors of Nrf2.
-Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent.
-Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent .
-Oridonin:
-Wogonin: although its effects might be cell‑ and dose‑specific.
- Withaferin A

Scientific Papers found: Click to Expand⟱
8234- LCA,    Licochalcone A: A Potential Multitarget Drug for Alzheimer’s Disease Treatment
- Review, AD, NA
*neuroP↑, *PTP1B↓, *cognitive↑, *BDNF↑, *TrkB↝, *cJun↓, *p‑tau↓, *AChE↓, *Ach↑, *Aβ↓, *antiOx↑, *NRF2↑, *AntiViral↑, *Obesity↓, *PI3K↑, *Akt↑, *mTOR↑, *memory↑, *BBB↑,
8237- LCA,    Role of Licochalcone A in Potential Pharmacological Therapy: A Review
- Review, Var, NA
*other↝, *Inflam↓, *Bacteria↓, *antiOx↑, *AntiP↑, *neuroP↑, *glucose↝, *lipid-P↓, PKCδ↓, P70S6K↓, Akt↓, ER Stress↑, Apoptosis↑, Ca+2↑, PI3K↓, mTOR↓, Casp3↑, Bcl-2↓, Cyt‑c↑, BAX↑, cl‑PARP↑, cycD1/CCND1↑, ROS↑, CHOP/DDIT3↑, ERK↑, p38↑, JNK↓, IAP1↓, XIAP↓, survivin↓, cFLIP↓, RIP1↓, EGFR↓, MET↓, HER2/EBBR2↓, p‑4E-BP1↓, PERK↑, eIF2α↑, PD-L1↓, HK2↓, Glycolysis↓, Sp1/3/4↓, FasL↑, MMP↓, ATP↓, TumAuto↑, WEE1↑, P21↑, CDK1↓, TumCCA↑, TumCMig↓, TumCI↓, ABCG2↓, HSP90↓, T-Cell↑, CD4+↑, CD25+↑, FOXP3↑, Imm↝, *Inflam↓, *NF-kB↓, *NRF2↑, *AntiArt↑,
8242- LCA,    Nrf2 signaling and autophagy are complementary in protecting lipopolysaccharide/d-galactosamine-induced acute liver injury by licochalcone A
- in-vivo, LiverDam, NA
*ALAT↓, *AST↓, *Inflam↓, *ROS↓, *TLR4↓, *MAPK↓, *NF-kB↓, *TXNIP↓, *NLRP3↓, *NRF2↑, *p62↑, *hepatoP↑, *autophagy↑,
8245- LCA,    Licochalcone A Upregulates Nrf2 Antioxidant Pathway and Thereby Alleviates Acetaminophen-Induced Hepatotoxicity
- in-vivo, LiverDam, NA
*hepatoP↑, *Apoptosis↓, *mtDam↓, *ROS↓, *NRF2↑, *Keap1↓, *ARE↑, *ALAT↓, *AST↓, *MDA↓, *MPO↓, *SOD↑, *GSH/GSSG↑, *Bcl-2↑, *BAX↓, *cl‑Casp3↓, *p‑cJun↓, *AIF↓, *Cyt‑c↓,
8246- LCA,    Licochalcone A activates Keap1-Nrf2 signaling to suppress arthritis via phosphorylation of p62 at serine 349
- in-vivo, Arthritis, NA
*AntiBio↑, *AntiTum↑, *Inflam↓, *AntiArt↑, *p62↑, *NRF2↑,
8207- LCA,    Licochalcone a Induces ROS-Mediated Apoptosis through TrxR1 Inactivation in Colorectal Cancer Cells
- in-vitro, CRC, HCT116
ROS↑, TumCCA↑, Apoptosis↑, eff↓, TrxR1↓, cDC2↓, Bcl-2↓, BAX↑, NRF2↓, p‑ASK1↑,
8219- LCA,    Licochalcone A Ameliorates Cognitive Dysfunction in an Alzheimer's Disease Model by Inhibiting Endoplasmic Reticulum Stress-Mediated Apoptosis
- in-vivo, AD, NA
*Dose↝, *cognitive↑, *Aβ↓, *ER Stress↓, *BioAv↑, *toxicity↓, *PERK↓, *eIF2α↓, *ATF4↓, *CHOP/DDIT3↓, *NRF2↑,
8222- LCA,    Licochalcone A Induces Cholangiocarcinoma Cell Death Via Suppression of Nrf2 and NF-κB Signaling Pathways
- in-vitro, CCA, KKU-100 - in-vitro, CCA, KKU-213 - in-vitro, CCA, KKU-214 - in-vitro, CCA, KKU-156 - in-vitro, 0-Reserved, KKU-452
TumCP?, TumCD?, ROS↑, NRF2↓, BAX↑, Cyt‑c↑, TumCMig↓, TumCCA↑, NF-kB↓, STAT3↓, cycD1/CCND1↓, VEGF↓, ICAM-1↓,
8223- LCA,    Lico A Enhances Nrf2-Mediated Defense Mechanisms against t-BHP-Induced Oxidative Stress and Cell Death via Akt and ERK Activation in RAW 264.7 Cells
- in-vitro, Nor, RAW264.7
*Apoptosis↓, *ROS↓, *GSH↑, *GCLM↑, *GCLC↑, *HO-1↑, *NRF2↑, *Keap1↓, *ARE↑, *Akt↑, *ERK↑, *PI3K↑,
8224- LCA,    3,3',4,4'-Tetrahydroxy-2-methoxychalcone from Glycyrrhiza uralensis roots inhibits HIF-1α and Nrf2, suppressing hypoxia-induced angiogenesis
- in-vitro, CRC, HCT116
Hif1a↓, NRF2↓, VEGF↓, HO-1↓, ROS↓,
8225- LCA,  Cisplatin,    Licochalcone A protects against cisplatin-induced acute kidney injury via the modulation of Nrf2/Keap1-mediated ferroptosis and apoptosis
- in-vivo, Nor, NA
*RenoP↑, *Urea↓, *BUN↓, *creat↓, *Apoptosis↓, *Ferroptosis↓, *Iron↓, *ROS↓, *lipid-P↓, *mtDam↓, *NRF2↑,
8229- LCA,    Licochalcone A: a review of its pharmacology activities and molecular mechanisms
- Review, Nor, NA
*Inflam↓, *NO↓, *NF-kB↓, *TAC↑, Apoptosis?, TumCCA↑, TumCI↓, TumMeta↓, TumCP↓, MAPK↓, Akt↓, IL6↓, IL8↓, VEGFR2/KDR/Flk1↓, LC3II↑, PI3K↓, mTOR↓, mtDam↑, MMP↓, *NRF2↑, *PGE2↓, *Obesity↓, *SIRT1↑, *AMPK↑, *AntiFungal↑, *AntiP↑, *BMD↑, *GastroP↑,
8230- LCA,    The Ameliorative Role of Lico A on Aflatoxin B1-Triggered Hepatotoxicity Partially by Activating Nrf2 Signal Pathway
- vitro+vivo, Nor, NA
*hepatoP↑, *ROS↓, *TLR4↓, *NF-kB↓, *MAPK↓, *NLRP3↓, *NRF2↑, *Inflam↓, *Pyro↓,

Showing Research Papers: 1 to 13 of 13

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 13

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

WEE1↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

HO-1↓, 1,   NRF2↓, 3,   ROS↓, 1,   ROS↑, 3,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   MMP↓, 2,   mtDam↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

Glycolysis↓, 1,   HK2↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Apoptosis?, 1,   Apoptosis↑, 2,   p‑ASK1↑, 1,   BAX↑, 3,   Bcl-2↓, 2,   Casp3↑, 1,   cFLIP↓, 1,   Cyt‑c↑, 2,   FasL↑, 1,   IAP1↓, 1,   JNK↓, 1,   MAPK↓, 1,   p38↑, 1,   RIP1↓, 1,   survivin↓, 1,   TumCD?, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,   Sp1/3/4↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   eIF2α↑, 1,   ER Stress↑, 1,   HSP90↓, 1,   PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   cycD1/CCND1↓, 1,   cycD1/CCND1↑, 1,   P21↑, 1,   TumCCA↑, 4,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑4E-BP1↓, 1,   cDC2↓, 1,   ERK↑, 1,   mTOR↓, 2,   P70S6K↓, 1,   PI3K↓, 2,   STAT3↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   MET↓, 1,   PKCδ↓, 1,   TumCI↓, 2,   TumCMig↓, 2,   TumCP?, 1,   TumCP↓, 1,   TumMeta↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 2,   VEGFR2/KDR/Flk1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD25+↑, 1,   CD4+↑, 1,   FOXP3↑, 1,   ICAM-1↓, 1,   IL6↓, 1,   IL8↓, 1,   Imm↝, 1,   NF-kB↓, 1,   PD-L1↓, 1,   T-Cell↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   eff↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   HER2/EBBR2↓, 1,   IL6↓, 1,   PD-L1↓, 1,  
Total Targets: 79

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiArt↑, 2,   AntiBio↑, 1,   AntiP↑, 2,   autophagy↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   ARE↑, 2,   Ferroptosis↓, 1,   GCLC↑, 1,   GCLM↑, 1,   GSH↑, 1,   GSH/GSSG↑, 1,   HO-1↑, 1,   Iron↓, 1,   Keap1↓, 2,   lipid-P↓, 2,   MDA↓, 1,   MPO↓, 1,   NRF2↑, 10,   ROS↓, 5,   SOD↑, 1,   TAC↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

AIF↓, 1,   mtDam↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 2,   AMPK↑, 1,   BUN↓, 1,   glucose↝, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 2,   Apoptosis↓, 3,   BAX↓, 1,   Bcl-2↑, 1,   cl‑Casp3↓, 1,   Cyt‑c↓, 1,   Ferroptosis↓, 1,   MAPK↓, 2,   Pyro↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

Ach↑, 1,   cJun↓, 1,   p‑cJun↓, 1,   other↝, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   eIF2α↓, 1,   ER Stress↓, 1,   PERK↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

p62↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↑, 1,   mTOR↑, 1,   PI3K↑, 2,  

Migration(tgid=13) ⓘ

PTP1B↓, 1,   TXNIP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

ATF4↓, 1,   NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   GastroP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 6,   NF-kB↓, 4,   PGE2↓, 1,   TLR4↓, 2,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   BDNF↑, 1,   p‑tau↓, 1,   TrkB↝, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 2,   NLRP3↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   Dose↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 2,   BMD↑, 1,   creat↓, 1,   Urea↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,   cognitive↑, 2,   hepatoP↑, 3,   memory↑, 1,   neuroP↑, 2,   Obesity↓, 2,   RenoP↑, 1,   toxicity↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   AntiViral↑, 1,   Bacteria↓, 1,  
Total Targets: 83

Scientific Paper Hit Count for: NRF2, nuclear factor erythroid 2-related factor 2
13 Licochalcone A
1 Cisplatin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:447  Target#:226  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page